C Difficile Infection

A northern Europe-based trial highlights the potential impact of streamlined and community-supported colonoscopy screening for cancer.

A recent randomized controlled trial showed the limitations of either option, despite being a cornerstone of care.

Analysis from a multicenter, randomized, double-blind, parallel group study comparing the drugs as induction and maintenance therapies in biologic-naïve patients.

There have been only 12 unique studies evaluating this treatment for the primary and secondary prevention of CDI, with only 1 conducted prospectively.

Only 2 of the households sampled featured an owner and pet who both tested positive for C. difficile.

The treatment was well-tolerated, with all serious treatment emergent adverse events considered not related to the treatment.

The results show 2.56% of the CDI group developed prostate cancer, compared to 7.79% in the control group in patients matched by age range and Charlson Comorbidity Index.

Standard infusion group had more patients with P. aeruginosa isolates from blood and respiratory cultures, ICU status at the start of therapy and longer duration of treatment.

The results show adherence to 6 quality indicators was linked to improvements in the post-intervention cohort with significant increases in C difficile testing, CRP testing, testing for latent tuberculosis, thromboprophylaxis, adequate corticosteroids prescription, and limitation of narcotics prescribed.

The results also show a decrease in antibiotic use, hospital length of stay, and overall cost to the patient.

Thus far, the phase 2 data on CP101 was generally positive for the treatment of recurrent C difficile infections.

Older age and use of various medications, including antibiotics, proton pump inhibitors, and corticosteroids were associated with a higher risk of developing C difficile infections.

The 2 strains identified were highly similar and exhibited differences of only 2 single-nucleotide polymorphisms.

SARS-CoV-2 infections cause microbiome dysbiosis in patient and possibly an increase in opportunistic pathogens and a decrease in beneficial bacteria.

The new polymerase chain reaction method was evaluated for specificity, sensitivity, and repeatability using 69 C difficile isolates and 74 fecal samples.

MDR colonization was associated with MDR infection and colonization and infection was linked to higher numbers and duration of antibiotic use.

The company announced they will no longer pursue approval for the treatment despite positive data from recent phase 2 trials.

Patients with COVID-19 and CDI had a higher incidence of sepsis, shock, ICU admission, and acute kidney injuries.

Individuals with level 3 care needs, participants with hypertension or stroke and residents who used canes were at a higher risk of developing norovirus-related diarrhea.

Hospital lengths of stay, costs, and readmissions were all reduced after implementing an antimicrobial stewardship program.

Mattresses, toilet floors, and room floors were places where C difficile was commonly detected in areas inhabited by C difficile infection positive populations.

The number of 30-day hospital readmissions because of CDI increased between 2010-2017.

The results show similar rates o colonized C difficile among pediatric patients and adult patients with cystic fibrosis.

This novel concept can benefit patients and clinicians alike by appropriately applying new technologies to identify bacteria more efficiently and decrease the time to optimal therapy.

There was no differences observed in total weight loss at both 6 and 18 months in the fecal microbiota transplantation and placebo groups.